Role of BET Bromodomain in Hematopoietic Differentiation from hESCs

Zi Cen Feng, Yu Qi Wen, Meng Ge Wang, Qian Tu, Hong Tao Wang, Zack Z. Wang, Jia Xi Zhou

Research output: Contribution to journalArticle


OBJECTIVE: To explore the role of bromodomain and extra terminal (BET) bromodomain in hematopoietic differentiation from human enbryonic stem cells (hESC). METHODS: The effect of BET hematopoietic inhibitor I-BET151 on hematopoietic differentiation from hESC was detected by using a monolayer hematopoietic defferentiation model, immunofluorescence, flow cytometry and real-time PCR; moreover the role of I-BET151 in process of hematopoietic differentiation was explored by adding I-BET151 in different differentiation stages. RESULTS: The analysis results of immunofluorescence, flow cytometry and real-time PCR showed that I-BET 151 significantly inhibited the generation of CD43 positive hematopoietic stem and progenitor cells (HSPCs). It was found that the addition of I-BET 151 in different stages, including APLNR+ lateral plate mesoderm production, CD34+CD31+ hemogenic endothelium (HEP) generation and endothelial-to-hematopoietic transition, significantly suppressed the generation of CD43 positive hematopoietic progenitor cells. CONCLUSION: I-BET 151 inhibites hematopoietic differentiation from hESCs at several stages, suggesting that the BET bromodomain plays important roles in multiple stages of hematopoietic differentiation from hESCs.

Original languageEnglish (US)
Pages (from-to)1186-1193
Number of pages8
JournalZhongguo shi yan xue ye xue za zhi
Issue number4
Publication statusPublished - Aug 1 2018
Externally publishedYes


ASJC Scopus subject areas

  • Medicine(all)

Cite this